[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652496":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":29,"collaborators":11,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":11,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":11,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":11,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":11},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"pirtobrutinib combined with camustine, etoposide, cytarabine, and mafaran (BEAM)","EXPERIMENTAL",null,[13],"Drug: pirtobrutinib combined with BEAM",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","pirtobrutinib combined with BEAM","pirtobrutinib 200mg oral qd D-8-D-2; camustine: 300mg\u002Fm2 vgtt qd D-8; etoposide: 100mg\u002Fm2\u002Fd vgtt q12h D-7-D-4; cytarabine: 200mg\u002Fm2\u002Fd vgtt q12h D-7-D-4 melphalan: 70mg\u002Fm2 vgtt qd D3-D-2.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Wei-Li Zhao professor","CONTACT","+862164370045","zwl_trial@163.com",{"name":27,"role":23,"phone":24,"phoneExt":11,"email":28},"Meng-Meng Ji doctor","jimengmeng025@163.com",{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Zhao Weili","professor","100652496","phase-2-pirtobrutinib-combined-with-beam-for-asct-in-relapsed-and-refractory-dlbcl-100652496",false,"NCT07774299","Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL","A Multicenter, Single-Arm Clinical Study of Pirtobrutinib Combined With Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preconditioning Regimen for ASCT in Relapsed and Refractory DLBCL","Inclusion Criteria:\n\n1. According to world Health Organization (WHO) classification of disease, diffuse large B-cell lymphoma was confirmed by histology, CR or PR after second-line and above treatment;\n2. 18≤ age ≤70 years old, male or female;\n3. ECOG score 0-2;\n4. No serious organic lesions in the main organs, meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment) :\n\n   1. White blood cell count ≥3.0×109\u002FL, absolute neutrophil count ≥1.5×109\u002FL, Hemoglobin ≥90g\u002FL, platelet ≥75×109\u002FL;\n   2. Total bilirubin ≤1.5× upper normal value (ULN);\n   3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× ULN; Bilirubin ≤1.5× ULN\n   4. Creatinine clearance was 44-133 mmol\u002FL;\n5. No cardiac dysfunction;\n6. Life expectancy over 3 months;\n7. The subject or his\u002Fher legal representative must provide written informed consent prior to conducting a special study examination or procedure.\n\nExclusion Criteria:\n\n1. Previously received autologous hematopoietic stem cell transplantation;\n2. Suffering from serious complications or severe infection;\n3. Central nervous system lymphoma was excluded;\n4. A history of other malignant tumors within 5 years, excluding early tumors treated for curative purposes;\n5. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.;\n6. HBsAg, HCV or HIV positive. Positive HBV and HCV serology is allowed, but DNA\u002FRNA testing must be negative;\n7. Left ventricular ejection fraction ≦ 50%;\n8. Laboratory test value during screening;\n\n   ① Neutrophils \\\u003C1.5×109\u002FL; Platelet \\\u003C75×109\u002FL;\n\n   ② Bilirubin was 1.5 times higher than the normal upper limit, transaminase was 2.5 times higher than the normal upper limit;\n\n   ③ The creatinine level is higher than 1.5 times the upper limit of normal value;\n9. Other concurrent and uncontrolled medical conditions considered by the investigator would affect the patient's participation in the study;\n10. Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol;\n11. Pregnant or lactating women;\n12. The researcher judged that the patients were not suitable for this study.","ALL","18 Years","70 Years",{"count":44,"type":45},28,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","This trial is a prospective, multi-center, single-arm clinical research. The intention is to evaluate the efficacy and safety of pirtobrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL patients.",[51],"DLBCL","NOT_YET_RECRUITING","2026-08-17",{"date":55,"type":56},"2026-08-19","ACTUAL",{"date":58,"type":45},"2026-08-25",{"date":60,"type":45},"2029-08-25",{"name":5,"class":6}]